Background: Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematomas (CSDH) with ethylene vinyl alcohol (EVOH) causes an evident patient discomfort due to meningeal nociceptors stimulation. The aim of this study was to assess safety and efficacy of intra-arterial lidocaine (IAL) before MMAE of CSDH with EVOH.Methods: We analyzed all consecutive patients with bilateral CSDH undergoing MMAE with EVOH. We used a monolateral IAL injection, with casual allocation. We assessed the headache felt by patients during embolization with the visual analog scale (VAS) and compared scores obtained after embolization of both sides. We followed the STROBE guidelines for case-control studies. Paired t-test and ?(2) test were used to compare the distribution of variables in IAL vs control group.Results: Between September 2021 and March 2023, 32 patients underwent bilateral MMAE with EVOH for a CSDH. Lidocaine treatment resulted in a substantially lower VAS score compared to the control group (median 3 vs 7, p < 0.001), with no sub-stantial side effect. Compliance also benefited from lidocaine administration.Conclusions: In patients with CSDH undergoing MMAE, IAL seems to reduce pain sensation associated with EVOH injection and to increase patients' compliance during treatment.

Lidocaine for headache prevention during chronic subdural hematoma embolization / Diana, Francesco; Romoli, Michele; Ricchetti, Francesca; Milonia, Luca; Salcuni, Andrea; Cirelli, Carlo; Ruzza, Alberto Di; Gaudino, Chiara; Iacobucci, Marta; Biraschi, Francesco. - In: INTERVENTIONAL NEURORADIOLOGY. - ISSN 1591-0199. - (2023), p. 15910199231198909. [10.1177/15910199231198909]

Lidocaine for headache prevention during chronic subdural hematoma embolization

Milonia, Luca;Iacobucci, Marta;
2023

Abstract

Background: Middle meningeal artery embolization (MMAE) for the management of chronic subdural hematomas (CSDH) with ethylene vinyl alcohol (EVOH) causes an evident patient discomfort due to meningeal nociceptors stimulation. The aim of this study was to assess safety and efficacy of intra-arterial lidocaine (IAL) before MMAE of CSDH with EVOH.Methods: We analyzed all consecutive patients with bilateral CSDH undergoing MMAE with EVOH. We used a monolateral IAL injection, with casual allocation. We assessed the headache felt by patients during embolization with the visual analog scale (VAS) and compared scores obtained after embolization of both sides. We followed the STROBE guidelines for case-control studies. Paired t-test and ?(2) test were used to compare the distribution of variables in IAL vs control group.Results: Between September 2021 and March 2023, 32 patients underwent bilateral MMAE with EVOH for a CSDH. Lidocaine treatment resulted in a substantially lower VAS score compared to the control group (median 3 vs 7, p < 0.001), with no sub-stantial side effect. Compliance also benefited from lidocaine administration.Conclusions: In patients with CSDH undergoing MMAE, IAL seems to reduce pain sensation associated with EVOH injection and to increase patients' compliance during treatment.
2023
Chronic subdural hematoma; VAS; endovascular embolization; intra-arterial lidocaine; middle meningeal artery
01 Pubblicazione su rivista::01a Articolo in rivista
Lidocaine for headache prevention during chronic subdural hematoma embolization / Diana, Francesco; Romoli, Michele; Ricchetti, Francesca; Milonia, Luca; Salcuni, Andrea; Cirelli, Carlo; Ruzza, Alberto Di; Gaudino, Chiara; Iacobucci, Marta; Biraschi, Francesco. - In: INTERVENTIONAL NEURORADIOLOGY. - ISSN 1591-0199. - (2023), p. 15910199231198909. [10.1177/15910199231198909]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1701302
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
social impact